Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Diagnostics’ PrimeStore MTM Successfully Evaluated by Public Health England for SARS-CoV-2 Inactivation

By HospiMedica International staff writers
Posted on 06 Oct 2020
EKF Diagnostics’ (Cardiff, UK) novel viral transport media PrimeStore MTM (Molecular Transport Medium) has been successfully evaluated for effective SARS-CoV-2 inactivation in a new study published by Public Health England (PHE).

To work safely with live SARS-CoV-2 samples requires the use of high-containment laboratories. More...
However, after inactivation SARS-CoV-2 material can be handled at a lower containment level, allowing more laboratories to undertake testing and thereby increasing COVID-19 testing capacity. EKF’s PrimeStore MTM sample collection device allows COVID-19 samples to be rapidly inactivated in the collection tube, avoiding contamination and preserving RNA without need for refrigeration. EKF is a contract manufacturer and supplier for the PrimeStore MTM, which is an FDA-cleared and CE-marked microbial nucleic acid storage and stabilization device, owned and created by Longhorn Vaccines and Diagnostics LLC (Bethesda, MD, USA).

PrimeStore MTM deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, and eliminating the risk of infection during transport and in laboratories. In addition to removing the need for cold chain storage of samples, RNA and DNA are perfectly preserved ready for safe testing immediately on arrival at a laboratory and without need for containment. PrimeStore MTM is the only FDA Class II cleared device for microbial nucleic acid storage and stabilization (RNA and DNA) available for the safe transportation of samples which may contain viruses.

The PHE study evaluated numerous commercially available reagents and laboratory formulations commonly used for viral inactivation protocols by public health agencies and research laboratories globally. All the reagents tested have been used during the current COVID-19 pandemic for sample transportation and subsequent molecular processing. A total of 23 commercial reagents designed for virus inactivation, clinical sample transportation and nucleic acid extraction were assessed by PHE for their ability to inactivate SARS-CoV-2.

The study used TCID50 and blind passage techniques to test for any infectious virus still recoverable from all samples treated with the inactivation reagents. Notably, the study showed that PrimeStore MTM was the only commercially available transport reagent from the many tested from which no residual virus was detectable by either TCID50 or by the passaging of treated purified sample. This demonstrates the efficacy and safety of PrimeStore MTM in inactivating live SARS-CoV-2 samples while maintaining the ability to detect the target viral RNA.





Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.